Balyasny Asset Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,300,604
Closed -$1.65M 2903
2024
Q4
$1.65M Buy
1,300,604
+1,126,569
+647% +$2.87M ﹤0.01% 1746
2024
Q3
$593K Buy
174,035
+136,068
+358% +$592K ﹤0.01% 2199
2024
Q2
$177K Sell
37,967
-254,743
-87% -$1.44M ﹤0.01% 2353
2024
Q1
$2.17M Buy
292,710
+233,387
+393% +$1.94M ﹤0.01% 1522
2023
Q4
$601K Buy
+59,323
New +$521K ﹤0.01% 1872
2023
Q1
Sell
-345,940
Closed -$3.07M 2780
2022
Q4
$3.07M Buy
345,940
+260,737
+306% +$2.86M 0.01% 1228
2022
Q3
$1.04M Sell
85,203
-229,044
-73% -$3.57M ﹤0.01% 1777
2022
Q2
$3.72M Buy
+314,247
New +$4.21M 0.01% 1075
2021
Q3
Sell
-29,902
Closed -$1.69M 2063
2021
Q2
$1.69M Buy
+29,902
New +$1.1M 0.01% 1076
2019
Q3
Sell
-118,993
Closed -$2.94M 1272
2019
Q2
$2.94M Buy
118,993
+90,126
+312% +$2.15M 0.02% 770
2019
Q1
$706K Sell
28,867
-10,197
-26% -$231K ﹤0.01% 1109
2018
Q4
$889K Buy
+39,064
New +$1.06M 0.01% 933
2018
Q3
Sell
-9,880
Closed -$354K 1748
2018
Q2
$354K Sell
9,880
-16,761
-63% -$593K ﹤0.01% 1461
2018
Q1
$883K Buy
+26,641
New +$949K ﹤0.01% 1262
2017
Q1
Sell
-94,800
Closed -$1.54M 1630
2016
Q4
$1.54M Buy
94,800
+34,800
+58% +$528K 0.01% 931
2016
Q3
$809K Buy
+60,000
New +$1.23M ﹤0.01% 700

Other funds holding EDIT

Balyasny Asset Management's EDIT Position: Q1 2025 in Review

Balyasny Asset Management sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 1,300,604 shares — an estimated $1.65M sold.

Balyasny Asset Management first reported a position in EDIT in Q3 2016 and held it in 16 quarters. The position peaked at $3.72M in Q2 2022. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

  • Balyasny Asset Management reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 1,300,604 Editas Medicine shares in Q1 2025, an estimated $1.65M.
  • Balyasny Asset Management first reported a position in Editas Medicine in Q3 2016 and held it in 16 quarters.
  • Balyasny Asset Management's Editas Medicine position peaked at $3.72M in Q2 2022.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.